Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
J C NicholsG Schwartz

Abstract

DAB389IL-2 is an interleukin-2 receptor (IL-2R) specific fusion protein with a molecular weight of 58 kD containing the enzymatic and translocation domains of diphtheria toxin (DT) and human IL-2. This fusion protein is able to direct the cytocidal action of the DT enzymatic region only to cells which bear the IL-2R. The human IL-2R exists in three forms: low, intermediate and high affinity. The high-affinity form is believed to be the biologically relevant form on mature, activated T-lymphocytes, B-lymphocytes and monocytes. DAB389IL-2 is able to bind selectively to the high-affinity IL-2R in a concentration-dependent manner, and once bound is internalised via receptor-mediated endocytosis. Upon acidification of the formed vesicle, the enzymatic portion of the fusion protein is believed to pass into the cytosol where it ultimately inhibits protein synthesis by inactivation of elongation factor-2, resulting in cell death. The constitutive expression of the IL-2R on certain leukaemic and lymphomatous cells of T and B cell origin has been reported to occur in patients with chronic lymphocytic leukaemia, cutaneous T cell lymphoma (CTCL), Hodgkin's disease and non-Hodgkin's lymphomas (NHLs). A multicentre DAB389IL-2 dose-escalation...Continue Reading

References

Sep 1, 1992·Journal of the American Academy of Dermatology·K B HollowayF A Ramos-Caro
Jul 17, 1992·Science·T TakeshitaK Sugamura
Aug 19, 1991·International Journal of Cancer. Journal International Du Cancer·P A BachaJ C Nichols
Nov 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P JolyB Varet
Jan 11, 1991·Journal of the American Academy of Dermatology·E A SpringerH H Roenigk
Mar 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·A M WeissmanR D Klausner
Nov 1, 1986·European Journal of Immunology·J W LowenthalB J Iacopetta
Aug 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·M TsudoT A Waldmann
Jan 1, 1972·Bulletin de la Société française de dermatologie et de syphiligraphie·E HadidaP Vallette
Nov 1, 1984·The Journal of Experimental Medicine·T A WaldmannW C Greene
Aug 1, 1982·The British Journal of Dermatology·L HammingaW A Van Vloten
Mar 1, 1993·CA: a Cancer Journal for Clinicians·E A AbelR T Hoppe

❮ Previous
Next ❯

Citations

Jun 12, 2002·Current Treatment Options in Oncology·R S Siegel, T M Kuzel
Feb 9, 2012·Current Treatment Options in Oncology·Tara BloomSteven T Rosen
Sep 24, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C BuskeW Hiddemann
Oct 2, 2001·Critical Reviews in Oncology/hematology·P McLaughlin
Aug 8, 2008·Future Oncology·Madeleine Duvic, Rakhshandra Talpur
Jan 28, 2010·Chemical Biology & Drug Design·Alexander Sturzu, Stefan Heckl
Oct 5, 2015·Dermatologic Clinics·Larisa J Geskin
Dec 23, 2003·Dermatologic Therapy·Alain H RookCarmela C Vittorio
Jan 20, 2007·British Journal of Haematology·Nam H DangLuis Fayad
Apr 24, 2012·Clinical Lymphoma, Myeloma & Leukemia·Rakhshandra Talpur, Madeleine Duvic
Jun 24, 2009·Molecular Oncology·Shai White-GilbertsonChristina Voelkel-Johnson
Sep 25, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Joseph H AntinDaniel Weisdorf
Apr 1, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Franz TrautingerSean Whittaker
Jan 27, 2016·Critical Reviews in Oncology/hematology·Pier Luigi ZinzaniStefano Pileri
Mar 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H Miles PrinceAndres Negro-Vilar
Jan 8, 2000·Dermatologic Clinics·M Duvic, J C Cather
Feb 26, 2000·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·A E FrankelE A Sausville
Aug 25, 2001·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·C C VittorioJ M Junkins-Hopkins
Nov 26, 2002·Hematology·Joseph M ConnorsFrancine M Foss
Feb 29, 2020·Molecular Oncology·Haoyu WangZhirui Wang
May 10, 2003·Clinical and Diagnostic Laboratory Immunology·Robert A JordanEdmund J Gosselin
Aug 2, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R S SiegelT M Kuzel
May 15, 2003·Cancer Investigation·Bernard J PoieszDavid Choi
Aug 17, 2019·Frontiers in Oncology·Shaheer Khan, Ahmed Sawas
Feb 15, 2007·European Surgical Research. Europäische Chirurgische Forschung. Recherches Chirurgicales Européennes·N ChibaM Kitajima
Apr 29, 2021·Seminars in Hematology·John C Reneau, Ryan A Wilcox
Jan 9, 2004·Hematology/oncology Clinics of North America·Francine M Foss, Thomas A Waldmann
Aug 6, 2008·Drug Discovery Today·Sirisha PotalaRama S Verma

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.